Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-21
    E.g., 2018-10-21

Archive Search

259517 items
3:35 PM, Oct 19, 2018  |  BC Extra | Company News

Management tracks: AbbVie, Adverum

AbbVie Inc. (NYSE:ABBV) said EVP and CFO William Chase will retire in mid-2019. Effective immediately, Chase becomes EVP of finance and administration until his retirement and VP and Controller Robert Michael will succeed Chase as...
3:27 PM, Oct 19, 2018  |  BC Extra | Politics & Policy

FDA asks peers to globalize generic drug development

FDA is calling on international regulatory authorities to develop harmonized guidelines on scientific and technical standards for generic drugs that would allow manufacturers to use the same data and applications to gain approval across multiple...
1:46 PM, Oct 19, 2018  |  BioCentury | Finance

Taiho ups its stakes

After bumping up its evergreen fund from $50 million to $300 million, Taiho Ventures LLC plans to increase its stakes in its portfolio companies. The strategic venture arm of Taiho Pharmaceutical Co. Ltd. launched in 2016...
12:38 PM, Oct 19, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Oxford Nanopore receives £50M investment from Amgen

Oxford Nanopore Technologies Ltd. (Oxford, U.K.) received an equity investment of £50 million ($65.6 million) on Oct. 18 from Amgen Inc. (NASDAQ:AMGN). Amgen's deCODE Genetics subsidiary uses Oxford Nanopore's nanopore-based DNA and RNA sequencing technology to...
12:37 PM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Regulatory

FDA panel votes in favor of Shire’s constipation product

FDA’s Gastrointestinal Drugs Advisory committee voted unanimously in favor of approving an NDA from Shire plc (LSE:SHP; NASDAQ:SHPG) for prucalopride to treat chronic idiopathic constipation (CIC). Its PDUFA date is Dec. 21. The panel voted 10-0...
12:35 PM, Oct 19, 2018  |  BC Week In Review | Company News  |  Deals

Sarepta gets gene therapy candidate, Lysogene extends runway

Lysogene S.A. (Euronext:LYS) granted Sarepta Therapeutics Inc. (NASDAQ:SRPT) exclusive, ex-European rights to LYS-SAF302, an adeno-associated virus (AAV)-mediated gene therapy. Sarepta will pay $15 million up front and make a $2.5 million equity investment in Lysogene,...
12:34 PM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

BioLineRx reports response, survival data for BL-8040, Keytruda combo in pancreatic cancer

BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX) reported data from the Phase IIa COMBAT/KEYNOTE-202 trial showing that BL-8040 plus Keytruda pembrolizumab led to a disease control rate (DCR) of 34.5%, including one partial response and nine cases...
12:32 PM, Oct 19, 2018  |  BC Week In Review | Financial News  |  Proposed Offerings

Reports say Innovent seeking $422M IPO in Hong Kong

Innovent Biologics Inc. (Suzhou, China) did not respond to inquiries regarding reports that the company is seeking to raise $422 million in an IPO on the Hong Kong stock exchange, which would value the company...
12:25 PM, Oct 19, 2018  |  BC Extra | Financial News

LogicBio marks week’s third IPO to miss price target

LogicBio Therapeutics Inc. (NASDAQ:LOGC) priced its IPO below its proposed range late Thursday, joining two other biotechs that missed their target price this week. But shares of the genome editing company jumped $1.90 (19%) to...
12:14 PM, Oct 19, 2018  |  BC Week In Review | Company News  |  Deals

HiFiBiO Therapeutics acquires H-Immune

HiFiBiO Therapeutics (Cambridge, Mass.) acquired H-Immune Therapeutics S.A.S. (Paris, France) for an undisclosed sum. H-Immune is developing a pipeline of immuno-oncology focused human antibodies generated using the company's in vitro immunization platform. The biotech spun...